Commonwealth Equity Services LLC bought a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the third quarter, HoldingsChannel reports. The fund bought 23,820 shares of the company’s stock, valued at approximately $2,394,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Kestra Private Wealth Services LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the third quarter worth about $534,000. Chicago Partners Investment Group LLC acquired a new position in shares of iShares U.S. Pharmaceuticals ETF in the third quarter worth about $210,000. Compass Financial Management LLC lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 321.0% in the third quarter. Compass Financial Management LLC now owns 23,689 shares of the company’s stock worth $2,381,000 after acquiring an additional 18,062 shares in the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC acquired a new position in shares of iShares U.S. Pharmaceuticals ETF in the third quarter worth about $452,000. Finally, Woodmont Investment Counsel LLC purchased a new position in iShares U.S. Pharmaceuticals ETF in the third quarter valued at about $560,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE opened at $104.34 on Friday. iShares U.S. Pharmaceuticals ETF has a one year low of $81.45 and a one year high of $112.29. The stock has a 50-day moving average price of $103.53 and a 200 day moving average price of $96.35. The company has a market capitalization of $1.64 billion, a P/E ratio of 33.66 and a beta of 0.47.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
